Clinical investigation on levofloxacin and azithromycin in the treatment of community-acquired pneumonia
Bo Zhang
Abstract
Bo Zhang
Abstract
Objective To evaluate the efficacy and safety of levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP).Methods Fifty-six patients with CAP were randomly divided into two groups:① treatment group:the patients were treated with levofloxacin and azithromycin. ② control group:the patients were treated with levofloxacin alone. Both groups were treated for 7~14 days. Efficacy and safety of levofloxacin and azithromycin in the treatment were observed.Results The overall efficacy was 96.42% for the treatment group and 82.14% for the control group. The results showed that there were significant differences between the two groups (P0.05);The rates of the side effects were 14.29% and 21.43%,respectively. There were no significant differences between the two groups (P0.05).Conclusion Levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP) can improve efficacy,shorten the course of disease and are well tolerated.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To evaluate the efficacy and safety of levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP).Methods Fifty-six patients with CAP were randomly divided into two groups:① treatment group:the patients were treated with levofloxacin and azithromycin. ② control group:the patients were treated with levofloxacin alone. Both groups were treated for 7~14 days. Efficacy and safety of levofloxacin and azithromycin in the treatment were observed.Results The overall efficacy was 96.42% for the treatment group and 82.14% for the control group. The results showed that there were significant differences between the two groups (P0.05);The rates of the side effects were 14.29% and 21.43%,respectively. There were no significant differences between the two groups (P0.05).Conclusion Levofloxacin and azithromycin in the treatment of community-acquired pneumonia (CAP) can improve efficacy,shorten the course of disease and are well tolerated.
Key concepts: Levofloxacin, Azithromycin, Medicine, Community-acquired pneumonia, Pneumonia, Internal medicine, Clinical efficacy, Treatment and control groups